At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
In Brief
A Phase 4 clinical trial evaluating Doravirine 100 Mg, Integrase strand transfer inhibitors, and 2 other interventions for HIV Infections. Completed, enrolled 147 participants across 27 sites.
Detailed Summary
The purpose of this study was to determine if people with HIV and obesity taking an antiretroviral treatment regimen containing an integrase strand transfer inhibitor (INSTI) with (tenofovir alafenamide/emtricitabine (TAF/FTC) would either slow their rate of weight gain, or even lose weight, over the span of about 1 year after a switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication) combined with either TAF/TFC or tenofovir disoproxil fumarate (TDF)/FTC.
Study Details
Timeline
Interventions
Participants received a 100 mg tablet by mouth daily with or without food.
INSTIs were acquired through the standard of care locally.
NRTIs (TAF/FTC) were acquired through the standard of care locally.
NRTIs (TDF/FTC) were acquired through the standard of care locally.